• Skip to main content
  • Skip to primary sidebar

An Inconvenient Truth: This Is a Woman

Don’t Get Angry, Get Active!

Hide Search

GlaxoSmithKline responds to FDA on Cervarix

H. Sandra Chevalier-Batik · July 1, 2008 ·

Glaxo plans to submit final Cervarix study data for approval

Issued – Monday 30 June 2008, London, UK & Philadelphia, US

GlaxoSmithKline today provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of Cervarix®, its vaccine to prevent cervical cancer.

GSK has submitted its response to questions raised by the FDA in their Complete Response Letter, received in December, 2007.  In addition, given that final data from GSK’s Phase III pivotal efficacy study, HPV-008, are expected to be available later this year, GSK has decided to augment its application for approval with these data to ensure they are included in the U.S. label. GSK anticipates submitting these data in the first half of 2009. The timing depends on reaching a certain number of cases in order to conduct the final analysis. An FDA action on the application is expected to take up to six months following this submission. Interim data from this study were filed in the original application for the vaccine in March, 2007. The company does not expect that new clinical studies will be required for approval.

“Study 008 is a key study that will be completing later this year, and we expect the final results will strengthen the U.S. label for Cervarix,” said Barbara Howe, M.D., Vice President and Director, North American Vaccine Development, GlaxoSmithKline. “We continue to have positive and productive discussions with the FDA and remain confident in the vaccine’s safety and efficacy profile. We look forward to bringing this important new cervical cancer vaccine to girls and women in the U.S.”

To date, GSK’s cervical cancer vaccine has been approved in 67 countries around the world including the 27 member countries of the European Union, Mexico, Australia, Singapore and the Philippines. Licensing applications have been submitted in more than 35 additional countries including Japan. GSK also submitted the vaccine to the World Health Organization (WHO) for prequalification in September 2007.

Notes to editors

Burden of cervical cancer
Worldwide, more than 500,000 women will be newly diagnosed with cervical cancer and over 280,000 women will die from it each year.1 In the United States, after breast cancer, cervical cancer is the second leading cause of cancer death in women ages 20 to 39.2

About GlaxoSmithKline
GlaxoSmithKline—one of the world’s leading research-based pharmaceutical and healthcare companies—is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, please visit www.gsk.com/media.

GlaxoSmithKline Biologicals (GSK Biologicals) is a leading global vaccine manufacturer committed to preventing disease in people of all ages with innovative vaccines and delivery systems. The division, headquartered in Belgium, is active in vaccine research, development and production with more than 30 vaccines currently available globally and 20 more in development. In 2007 GSK Biologicals distributed 1.1 billion doses of vaccines – an average of 3 million doses a day.

Cervarix® is a registered trademark of the GlaxoSmithKline group of companies.

GSK cautionary statement regarding forward-looking statements
Under the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group’s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’s Annual Report on Form 20-F for 2007.

References:

1.       World Health Organization. Initiative for Vaccine Research.  Accessed on May 2, 2007.

2.       Jemal A, Murray T, Ward E, Sammuels A et al. Cancer Statistics, 2005. Cancer Journal for Clinicians 2005; 55; 10-30

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Share

Filed Under: Cervarix Tagged With: Cervarix, Cervical Cancer Vaccine, GlaxoSmithKline, HPV-Associated Cervical Cancer, HPV-Vaccination

Primary Sidebar

Categories

  • Attention-Deficit/Hyperactivity Disorder Medications
  • Big Pharma Watch
  • Biotech Industry
  • Birth Control
  • Breast Cancer
  • cáncer de cuello uterino
  • Cancer Research
  • Cervarix
  • Cervical Cancer
  • Clinical Trials
  • Diabetes
  • Domestic Violence
  • Drug Approvals
  • Emotional Health
  • FDA
  • FDA Black Box Warning
  • FDA Clinical Trials
  • FDA Failure To Protect
  • FDA Product Recall
  • Follow The Money
  • Gardasil
  • Gardasil®
  • Gender Bias
  • Gender Politics
  • genital warts
  • Guillain-Barre Syndrome
  • Hormone Cycle
  • HPV Infection
  • HPV Vaccine
  • HRT
  • HRT Side Effects
  • Influenza A Virus H1N1 Strain
  • Mammograms
  • Mandatory HPV Vaccination Policies
  • Medical Technology
  • Menopause
  • MERCK Watch
  • MMR vaccine
  • National Vaccine Injury Compensation Program
  • PAP Test
  • Prescription Drug Side Effects
  • Proactive Nutrition
  • Product Recall
  • Reproductive Health
  • Sexual Dysfunction
  • Sleep Loss
  • STD Infection
  • Stroke
  • Take Action!
  • Uncategorized
  • Unwanted Pregnancy
  • Vaccination Policy
  • VAERS
  • vaginal yeast infection
  • Virginity
  • Weight Gain
  • Women's Health
  • Women's Rights
  • Work Place Issues
  • World Health Organization
  • Yeast Infection
  • Your Body/Your Self

Archives

  • February 2010
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • March 2006
  • September 2005
  • June 2005
  • May 2005
  • December 2004
April 2025
S M T W T F S
 12345
6789101112
13141516171819
20212223242526
27282930  
« Feb    

Breast Cancer

  • Cancer Advocacy

Health Advocacy

  • Women’s Universal Health Initiative

Syndication

  • FDA MedWatch

Tags

Big Pharma Watch Birth Control Breast Cancer Cancer Cancer Research CDC Cervarix Cervical Cancer Children's Health Exploitive Behavior FDA FDA Approvals FDA Clinical Trials FDA Failure To Protect FDA Press Release Follow The Money Gardasil Gardasil Adverse Event Gardasil® GlaxoSmithKline GlaxoSmithKline Cervarix Gynecology H1N1 "swine flu" virus H1N1 pandemic influenza preparedness efforts Health Advisory HPV HPV-Associated Cervical Cancer HPV-Vaccination HPV Infection HPV Vaccine HRT Human Papillomavirus (HPV) Infection Merck PAP SMEAR PAP Test Proactive Nutrition Questionable Medicine STD Infection STD Vaccination swine flu vaccine Swine flu vaccine production Take Action! Uncategorized Woman’s Health Your Body/Your Self

Copyright © 2010-2025 Hands On WordPress · All Rights Reserved